Quince Therapeutics Receives Dual Nasdaq Delisting Notices for Bid Price and Market Value Deficiencies

summarizeSummary

Quince Therapeutics, Inc. has received notices from Nasdaq regarding non-compliance with both the minimum $1.00 bid price and $50 million market value of listed securities requirements, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Received Nasdaq Bid Price Notice

  On March 16, 2026, the company received a notice from Nasdaq for non-compliance with the $1.00 minimum bid price rule (Listing Rule 5450(a)(1)) for 30 consecutive business days.

• Received Nasdaq Market Value of Listed Securities (MVLS) Notice

  On March 17, 2026, the company received a notice from Nasdaq for non-compliance with the $50 million MVLS requirement (Listing Rule 5450(b)(2)(A)) for 30 consecutive business days.

• 180-Day Compliance Period Initiated

  The company has a period of 180 calendar days, until September 14, 2026, to regain compliance with both the Minimum Bid Price and MVLS Requirements.

• Potential Delisting Risk

  Failure to regain compliance could result in delisting from the Nasdaq Global Select Market, though the stock will continue to trade during the compliance period.

auto_awesomeAnalysis

Quince Therapeutics, Inc. faces a critical challenge to maintain its Nasdaq listing, having received notices for failing to meet both the minimum $1.00 bid price and the $50 million market value of listed securities requirements. With a current stock price of $0.0871 and a market cap of approximately $4.45 million, the company is significantly below both thresholds. Regaining compliance within the 180-day period will likely necessitate a reverse stock split to address the bid price and a substantial increase in valuation to meet the market value requirement, or a transfer to the Nasdaq Capital Market. Failure to comply could lead to delisting, which would severely impact the company's liquidity and investor confidence.